Tag: olivier michielin & vincent zoete group

  • The quest for small-molecule cancer immunotherapeutics

    If you are working in computer-aided drug design, this in silico talk is for you: SIB Senior Research Scientist Ute Röhrig takes you on a journey to push the boundaries of knowledge around IDO1 and its role in immunotherapy resistance.

  • Equality, Diversity, Inclusion

    About Equality, Diversity, Inclusion (EDI) Both as an employer, and as the ambassador of the Swiss bioinformatics community, SIB has a critical role to play in ensuring and fostering diversity and equal opportunities in the workplace as well as in...

  • Addex and SIB receive Innosuisse grant to repurpose potent dopamine antagonist

    Addex Therapeutics and SIB have been awarded a CHF600K Innosuisse grant to apply computational approaches developed by SIB to identify new therapeutic indications for a potent and selective dopamine D1 receptor antagonist.

  • Joining forces to develop new approaches to cancer immunotherapy

    Interdisciplinarity: UNIL, CHUV, EPFL and SIB join forces to develop new approaches to cancer immunotherapy

  • Understanding precision medicine with PrecisionMed.ch

    The PrecisionMed.ch website, developed by the SIB Swiss Institute of Bioinformatics, in collaboration with the University of Lausanne and the CHUV (Lausanne University Hospital), with the support of the SantéPerSo initiative, offers illustrated...

  • One million jobs on SIB's computer-aided drug design software platform!

    On 16 December 2018, the count of total jobs run on the SIB Resource SwissDrugDesign passed the symbolic one-million mark.

  • Precision medicine and the role of bioinformatics: four short films to understand

    Bioinformatics is fundamental to precision medicine. But why? How do hospitals and researchers benefit from bioinformatics to help patients? Canal9 TV Channel, the Oncology department of UNIL/CHUV and SIB all set out together to find answers to...

  • Olivier Michielin - Vincent Zoete's group

    What we do The Molecular Modelling Group studies molecular interactions using modelling techniques such as homology modelling, molecular dynamics, docking and free energy simulations. Our main activity consists in developing and applying methods...

  • Vincent Zoete - Olivier Michielin's group

    What we do The Molecular Modelling Group studies molecular interactions using modelling techniques such as homology modelling, molecular dynamics, docking and free energy simulations. Our main activity consists in developing and applying methods...

  • "Personalized health, health tailor-made"

    Discover the story of the patients for whom personalized medicine is already a reality. A TV documentary invites you to follow them with a team of oncologists, pathologists, biologists and bioinformaticians, in their search for a treatment against...

  • Outcome of SPHN first project call: a focus on SIB-led projects

    The National Steering Board of SPHN has recently approved the 15 projects that will help develop the infrastructure required to make health-related data interoperable and shareable across Switzerland.

  • The Drug Design Workshop: tomorrow’s drugs at your fingertips

    Bringing medicinal chemistry and bioinformatics to the layman, by using a didactic online platform based on professional tools, is the goal of the Drug Design Workshop. Developed in 2015 by SIB researchers, together with training and outreach...

  • SIB IN THE NEWS: DRUG DESIGN AND OUTREACH

    Today in the national news, Marie-Claude Blatter (Responsible - SIB Outreach activities) and Vincent Zoete (Associate director - Molecular Modelling group) presented SIB's role in drug design and bioinformatics outreach on the Radio Télévision...

  • SIB Resources

    Identifying and supporting SIB Resources Every four years, the Institute’s External Scientific Advisory Board (SAB) provides recommendations on the portfolio of SIB-supported Resources. By taking into account competitive criteria – such as the...